Targeting TIGIT
Targeting TIGIT: Understanding New Approaches for Inhibiting the Immune Checkpoint Pathway

Released: April 07, 2022

Expiration: April 06, 2023

Diwakar Davar
Diwakar Davar, MD
Jyoti D. Patel
Jyoti D. Patel, MD

Activity

Progress
1
Course Completed
In this episode, Jyoti D. Patel, MD, and Diwakar Davar, MD, discuss several studies investigating agents targeting TIGIT, an emerging immune checkpoint target with promising early-phase clinical trial results. The episode includes a comprehensive explanation of TIGIT, how the TIGIT pathway functions, and the potential role of TIGIT inhibition for the treatment of cancer, including analyses from ongoing clinical trials such as CITYSCAPE, PACIFIC-8, ARC-7, and SKYSCRAPER-01.